Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base

Executive Summary

With Gilotrif sales building over time, private Boehringer Ingelheim turns its focus to broad development program for its third-generation EGFR inhibitor olmutinib, with ambition to become a leader in lung cancer.

Advertisement

Related Content

Boehringer Ingelheim's Partnering Focus: An Interview With Ioannis Sapountzis
Surprise Boehringer Decision Turns Hanmi Investors’ Hopes To Despair
Clovis Pulls Plug On Rociletinib On Expected FDA Rejection
Head-To-Head Lung Data Support Boehringer’s Gilotrif Over Iressa
AstraZeneca Scores Lung Cancer Touchdown, While Clovis Fumbles
Boehringer Joins Next Generation Via Hanmi EGFR Inhibitor Deal
AstraZeneca’s Iressa, Now Resurrected, Faces Daunting U.S. EGFR Market
Third-Generation EGFR Inhibitors’ Safety Profiles Under Scrutiny At ASCO
Boehringer Launches Gilotrif At $5,500/Month, Just Under Entrenched Tarceva
Boehringer Banks On Cancer For Future Growth

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097062

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel